Adimmune Corp Valuation

4142 Stock  TWD 21.20  0.10  0.47%   
At this time, the firm appears to be overvalued. Adimmune Corp shows a prevailing Real Value of NT$18.66 per share. The current price of the firm is NT$21.2. Our model approximates the value of Adimmune Corp from analyzing the firm fundamentals such as Current Valuation of 15.44 B, return on equity of 0.0655, and Profit Margin of 0.21 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
21.20
Please note that Adimmune Corp's price fluctuation is very steady at this time. Calculation of the real value of Adimmune Corp is based on 3 months time horizon. Increasing Adimmune Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Adimmune stock is determined by what a typical buyer is willing to pay for full or partial control of Adimmune Corp. Since Adimmune Corp is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Adimmune Stock. However, Adimmune Corp's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  21.2 Real  18.66 Hype  21.2
The intrinsic value of Adimmune Corp's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adimmune Corp's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
18.66
Real Value
23.32
Upside
Estimating the potential upside or downside of Adimmune Corp helps investors to forecast how Adimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adimmune Corp more accurately as focusing exclusively on Adimmune Corp's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
20.0321.2022.37
Details

Adimmune Corp Total Value Analysis

Adimmune Corp is presently anticipated to have takeover price of 15.44 B with market capitalization of 17.01 B, debt of 1.27 B, and cash on hands of 654.9 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Adimmune Corp fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
15.44 B
17.01 B
1.27 B
654.9 M

Adimmune Corp Investor Information

About 17.0% of the company shares are owned by insiders or employees . The book value of Adimmune Corp was presently reported as 14.63. The company last dividend was issued on the 14th of September 2021. Adimmune Corp had 1323:1256 split on the 18th of April 2019. Based on the analysis of Adimmune Corp's profitability, liquidity, and operating efficiency, Adimmune Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.

Adimmune Corp Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adimmune Corp has an asset utilization ratio of 20.49 percent. This indicates that the Company is making NT$0.2 for each dollar of assets. An increasing asset utilization means that Adimmune Corp is more efficient with each dollar of assets it utilizes for everyday operations.

Adimmune Corp Ownership Allocation

Adimmune Corp holds a total of 421.51 Million outstanding shares. Adimmune Corp shows 16.9 percent of its outstanding shares held by insiders and 15.86 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Adimmune Corp Profitability Analysis

The company reported the revenue of 1.64 B. Net Income was 43.07 M with profit before overhead, payroll, taxes, and interest of 464.14 M.

About Adimmune Corp Valuation

Our relative valuation model uses a comparative analysis of Adimmune Corp. We calculate exposure to Adimmune Corp's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adimmune Corp's related companies.
Adimmune Corporation manufactures and sells human vaccines in Taiwan. Adimmune Corporation was founded in 1965 and is based in Taichung City, Taiwan. ADIMMUNE CORPORATION operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange. It employs 384 people.

8 Steps to conduct Adimmune Corp's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Adimmune Corp's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Adimmune Corp's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Adimmune Corp's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Adimmune Corp's revenue streams: Identify Adimmune Corp's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Adimmune Corp's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Adimmune Corp's growth potential: Evaluate Adimmune Corp's management, business model, and growth potential.
  • Determine Adimmune Corp's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Adimmune Corp's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Additional Tools for Adimmune Stock Analysis

When running Adimmune Corp's price analysis, check to measure Adimmune Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adimmune Corp is operating at the current time. Most of Adimmune Corp's value examination focuses on studying past and present price action to predict the probability of Adimmune Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adimmune Corp's price. Additionally, you may evaluate how the addition of Adimmune Corp to your portfolios can decrease your overall portfolio volatility.